Or, we are in the midst of a vicious cycle here.
Post# of 36568
(Total Views: 264)
Posted On: 09/18/2020 9:04:08 AM
Or, we are in the midst of a vicious cycle here.
NGIO does not have the money to complete the lab testing, and BARDA is only willing to approve the application and provide extra funding to advance the vaccine development based on positive lab results.
And THIS is what I do not understand about BARDA. They must be aware that GNBT/NGIO is a small company and is struggeling financially. So assuming that all the mRNA, RNA and DNA developments have the same off target issues as AstraZeneca seems to already have, and they all end up stopping their Phase III trials. And GNBT/NGIO might have the only other significantly different technology that could provide a vaccine without these side effects.
Then I see this as BARDA's duty to provide GNBT/NGIO with enough funding such that financial issues that they currently have do not stand in their way of a vaccine development, but here they seem to make a positive decision denpendent on positive lab results, which may have caused GNBT to jump through hoops that are surely not beneficial for the company or us shareholders.
BARDA is supposed to make sure that every company that has a viable, realistic shot at developing a vaccine, has all the resources/funding available to get the development done as quickly as humanly possible, but that does not seem to be the case for NGIO, as they have very limited capital available, and that in turn holds up the fastest possible progress.
Why THE HECK can't BARDA give them a first milestone payment in order to be able to provide the extra information (lab tests), and then define additional milestones that they have to reach, and upon completion receive the larger and larger payments. They are giving 100s of Millions of Dollars to Big Pharma, and are not able to give 5 Mill. to GNBT, just to make sure that they "survive" and no additional delays are inflicted in their development due to the lack of appropriate funding? This truly blows my mind, as this makes ZERO sense to me!!!
NGIO does not have the money to complete the lab testing, and BARDA is only willing to approve the application and provide extra funding to advance the vaccine development based on positive lab results.
And THIS is what I do not understand about BARDA. They must be aware that GNBT/NGIO is a small company and is struggeling financially. So assuming that all the mRNA, RNA and DNA developments have the same off target issues as AstraZeneca seems to already have, and they all end up stopping their Phase III trials. And GNBT/NGIO might have the only other significantly different technology that could provide a vaccine without these side effects.
Then I see this as BARDA's duty to provide GNBT/NGIO with enough funding such that financial issues that they currently have do not stand in their way of a vaccine development, but here they seem to make a positive decision denpendent on positive lab results, which may have caused GNBT to jump through hoops that are surely not beneficial for the company or us shareholders.
BARDA is supposed to make sure that every company that has a viable, realistic shot at developing a vaccine, has all the resources/funding available to get the development done as quickly as humanly possible, but that does not seem to be the case for NGIO, as they have very limited capital available, and that in turn holds up the fastest possible progress.
Why THE HECK can't BARDA give them a first milestone payment in order to be able to provide the extra information (lab tests), and then define additional milestones that they have to reach, and upon completion receive the larger and larger payments. They are giving 100s of Millions of Dollars to Big Pharma, and are not able to give 5 Mill. to GNBT, just to make sure that they "survive" and no additional delays are inflicted in their development due to the lack of appropriate funding? This truly blows my mind, as this makes ZERO sense to me!!!
(0)
(0)